Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Stopped early · Phase 1

Conditions studied: Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC)

In brief

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.

Key facts

Study ID: NCT05909995
Run by: Incyte Corporation
People needed: 8
Starts: 2023-08-29
Expected to finish: 2024-11-11
Last updated by the study team: 2025-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Prior systemic therapy, diagnoses and disease setting as follows:
For Part 1 (dose escalation), and no history of treatment with anti-CTLA-4 or anti-PD-(L)1 therapy and one of the following,
Unresectable or metastatic cutaneous melanoma, or
Unresectable of metastatic Child-Pugh Class A NDD not eligible for surgical and/or locoregional therapy, or
Intermediate or poor-risk advanced clear cell RCC, or
MSI-H or dMMR metastatic CRC and able to provide fresh or archival tumor tissue for central confirmation of MSI-H or dMMR.
For Part 2 (dose expansion), IO treatment -naïve, e.g., no prior receipt of an anti PD-1, anti-PD-L1 or PD-L1, anti-CTLA-4, GITR, LAG3, TIM3, OX-40, IL-2, 4-1BB or other immune modulator, and have not received prior systemic therapy and one of the following,
Unresectable or metastatic Child-Pugh Class A HCC not eligible for surgical and/or locoregional therapy, or
Intermediate - or poor-risk advanced clear cell RCC.
ECOG performance score of 0 or 1.
Life expectancy > 3 months, in the opinion of the investigator.
Histologically confirmed solid tumors with measurable disease per RECIST v1.1.
Exception: HCC may be diagnoses based on cross-sectional multiphasic imagining using the AASLD criteria.
Willingness to avoid pregnancy or fathering children.

You may not qualify if…

Known history of an additional malignancy.
Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal disease.
Toxicity from prior therapy that has not recovered.
Received thoracic radiation within 6 months of the first dose of study treatment.
Participation in another interventional clinical study while receiving INCB099280.
Impaired cardiac function of clinically significant cardiac disease.
History of evidence of interstitial lung disease including non-infections pneumonitis.
Presence of gastrointestinal condition that may affect drug absorption
Any autoimmune disease requiring systemic treatment in the past 5 years.
Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent
Active infection requiring systemic therapy.
History of organ transplantation, including allogeneic stem cell transplantation.
Receipt of system antibiotics within 28 days of first dose of study treatment.
Probiotic usage is prohibited during the screening and throughout the study treatment period.
Received a live vaccine within 28 days of planned start of study drug.
Laboratory values outside the Protocol-defined ranges.
Other protocol-defined Inclusion/Exclusion Criteria may apply.

Where it is running

Valkyrie Clinical Trials — Los Angeles, California, United States
UC Irvine Medical Center — Orange, California, United States
Sharp Memorial Hospital — San Diego, California, United States
Henry Ford Health System — Detroit, Michigan, United States
Alliance For Multispecialty Research Llc — Knoxville, Tennessee, United States
Princess Margaret Cancer Center — Toronto, Ontario, Canada
Johese Clinical Research: Midstream — Centurion, South Africa
Mary Potter Oncology Centre — Pretoria, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.